Literature DB >> 17350362

Elective high-risk percutaneous coronary interventions supported by extracorporeal life support.

Jindra Vainer1, Vincent van Ommen, Jos Maessen, Gijs Geskes, Leon Lamerichs, Johannes Waltenberger.   

Abstract

This study investigated the feasibility of high-risk percutaneous coronary intervention (PCI) in hemodynamically unstable patients supported by modified cardiopulmonary bypass (extracorporeal life support [ELS]). Over a 38-month period, 15 patients (10 men, 5 women, mean age 72 +/- 9 years, mean ejection fraction 34 +/- 15%, angina pectoris New York Heart Association class III to IV) who were not eligible for coronary artery bypass grafting because of high co-morbidity underwent elective high-risk PCI supported by ELS. All lesions were technically challenging. ELS perfusion cannulas in the femoral artery and vein were surgically inserted and removed. Procedural success was achieved in 14 of 15 patients. After a mean perfusion duration of 88 +/- 37 minutes, all patients were weaned from the ELS in the catheterization laboratory. The patients were ventilated for 5.1 +/- 3.3 hours. Blood transfusion was given to 8 patients. Apart from 2 groin bleedings, no other complications occurred. Patients left our hospital after 3.2 +/- 2.8 days. Of the 4 patients who died during the 15 +/- 12-month follow-up, 1 died of a noncardiac cause. In conclusion, in highly selected patients ineligible for bypass surgery, ELS-supported PCI can be performed with promising short- and long-term clinical outcomes. This complex procedure is a safe alternative whenever other options for revascularization are exhausted.

Entities:  

Mesh:

Year:  2007        PMID: 17350362     DOI: 10.1016/j.amjcard.2006.10.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Short-term Mechanical Circulatory Support with a Centrifugal Pump - Results of Peripheral Extracorporeal Membrane Oxygenator According to Clinical Situation.

Authors:  Woo Surng Lee; Hyun Keun Chee; Meong Gun Song; Yo Han Kim; Je Kyoun Shin; Jun Seok Kim; Song Am Lee; Jae Joon Hwang
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-02-12

2.  Veno-Arterial Extracorporeal Membrane Oxygenation in Elective High-Risk Percutaneous Coronary Interventions.

Authors:  Ming Bai; Andong Lu; Chenliang Pan; Sixiong Hu; Wenjing Qu; Jing Zhao; Bo Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-26

3.  Extracorporeal Membrane Oxygenation during Percutaneous Coronary Intervention in Patients with Coronary Heart Disease.

Authors:  Oleh A Loskutov; Olexandr M Druzhyna; Dmytro O Dziuba; Stepan R Maruniak; Dmytro O Loskutov; Sergii F Veremchuk; Havryil I Kovtun; Borys M Todurov
Journal:  J Extra Corpor Technol       Date:  2020-09

4.  Percutaneous cardiopulmonary support-supported percutaneous coronary intervention: a single center experience.

Authors:  Sung Soo Cho; Chang-Myung Oh; Ji-Yong Jang; Hee Tae Yu; Woo-Dae Bang; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Won-Heum Shim; Seung-Yun Cho; Yangsoo Jang
Journal:  Korean Circ J       Date:  2011-06-30       Impact factor: 3.243

5.  Results of Extracorporeal Membrane Oxygenation (ECMO) Support before Coronary Reperfusion in Cardiogenic Shock with Acute Myocardial Infarction.

Authors:  Eui Suk Chung; Cheong Lim; Hae-Young Lee; Jin-Ho Choi; Jeong-Sang Lee; Kay-Hyun Park
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-08-18

6.  Short-Term Outcomes of Elective High-Risk PCI with Extracorporeal Membrane Oxygenation Support: A Single-Centre Registry.

Authors:  Alexander M Griffioen; Stijn C H Van Den Oord; Marleen H Van Wely; Gerard C Swart; Herbert B Van Wetten; Peter W Danse; Peter Damman; Niels Van Royen; Robert Jan M Van Geuns
Journal:  J Interv Cardiol       Date:  2022-09-16       Impact factor: 1.776

7.  Can we have a rationalized selection of intra-aortic balloon pump, Impella, and extracorporeal membrane oxygenation in the catheterization laboratory?

Authors:  Giulio Russo; Francesco Burzotta; Cristina Aurigemma; Daniela Pedicino; Enrico Romagnoli; Carlo Trani
Journal:  Cardiol J       Date:  2020-12-21       Impact factor: 2.737

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.